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The Pharmaceutical Paradox: Helping and Harming the Developing World
Abstract
Pharmaceutical companies are in quite a predicament. With the majority of the global disease burden
resting on the developing world and the vast majority of wealth residing in industrialized countries, these
corporations are caught in a constant struggle between the altruistic inclinations they are expected to
espouse and their responsibility to turn a profit. With the international community placing unprecedented
emphasis on the universal right to health, the pharmaceutical industry has become a central facet of
humanitarian work. In recent years, wealthy governments have funneled vast sums of money toward
treating the world’s poor and the United Nations has allocated four of its eight Millennium Development
Goals to specifically address health concerns. A passing glance at the issues most plaguing the world
today will easily explain this new focus: one billion people worldwide lack access to clean water, eleven
million die every year from infectious diseases, and the World Health Organization (WHO) now estimates
the number of AIDS-related deaths to exceed three million annually. These tragedies produce ripple
effects that can be felt throughout the inflicted nations and, because of our globalized society, throughout
the world. We live amidst a global health crisis of the highest degree - one that simply cannot be
addressed without the active participation of the pharmaceutical industry.
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Pharmaceutical companies are in quite a predicament. With the majority of the
global disease burden resting on the developing world and the vast majority of wealth
residing in industrialized countries, these corporations are caught in a constant struggle
between the altruistic inclinations they are expected to espouse and their responsibility to
turn a profit. With the international community placing unprecedented emphasis on the
universal right to health, the pharmaceutical industry has become a central facet of
humanitarian work. In recent years, wealthy governments have funneled vast sums of
money toward treating the world’s poor and the United Nations has allocated four of its
eight Millennium Development Goals to specifically address health concerns. 1 A passing
glance at the issues most plaguing the world today will easily explain this new focus: one
billion people worldwide lack access to clean water, 2 eleven million die every year from
infectious diseases, 3 and the World Health Organization (WHO) now estimates the
number of AIDS-related deaths to exceed three million annually. 4 These tragedies
produce ripple effects that can be felt throughout the inflicted nations and, because of our
globalized society, throughout the world. We live amidst a global health crisis of the
highest degree—one that simply cannot be addressed without the active participation of
the pharmaceutical industry.
But what should we realistically expect from these seeming hybrids of humanitarian actors
and corporate entrepreneurs? Certainly we can acknowledge that the products they market are
unlike most other commodities. Lifesaving medicines clearly deserve different consideration
than an MP3 player or state-of-the-art vacuum. Yet, trying to fulfill both a benevolent agenda
1
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while maintaining sustainable profits is problematic. It has caused these corporations to adopt
policies that, paradoxically, harm the developing world. This merely underlines the fact that
pharmaceutical companies will act first on their commercial interests and not simply on
humanitarian impulses. Albeit far from the ideal that many of us hope for, understanding this
reality and garnering more appropriate expectations of these businesses is an essential part of
making progress in the field global health and humanitarianism more broadly.
Patent Protection in the Developing World
One of the most controversial issues facing the pharmaceutical industry today is
that of patent protection on essential medicines. 5 Patents are defined as “monopolies
granted by the State for a specified length of time for the commercial exploitation of a
scientific or technological invention,” the goal of which is ultimately to spur innovation. 6
The Pharmaceutical Research and Manufacturers of America (PhRMA), an organization
that represents the nation’s leading pharmaceutical companies, argues that such patents
“protect their huge investments in researching and developing new drugs,” without which
they would be unable to “recoup their costs and reinvest in other research projects.” 7
These R&D costs can add up to hundreds of millions of dollars to produce a single new
drug, thus giving pharmaceutical companies a strong stake in seeing their patents
protected across the globe. 8 Conveniently for them, the pharmaceutical lobby is an
powerful force in Washington. These pharmaceutical corporations have great resources at

5

Tarullo, Daniel. “WTO, Developing Countries, and Regionalism.” American Enterprise Institute,
Washington. 3 Oct. 2006.
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<http://www.phrma.org/index.php?option=com_content&task=view&id=123&Itemid=109&cat=Intellectua
l+Property>
8
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their disposal and they know how to use them effectively. GlaxoSmithKline alone brings
in $27.2 billion dollars a year, giving it significant pull amongst policymakers. 9 In 2001,
the pharmaceutical industry had 625 registered lobbyists in DC and a combined lobbying
and campaign budget of $197 million from 1999-2000. 10 Pfizer’s marketing department
alone is larger than the entirety of the World Health Organization. 11 With an industry
holding such wealth and power, one would correctly expect policies to be shaped to its
benefit.
The inclusion of intellectual property in the World Trade Organization’s agenda is
directly traceable to the efforts of two powerful U.S. companies, one of which was
Pfizer. 12 With great pressure from the pharmaceutical lobby, the United States backed the
signing of the Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS). The agreement established a minimum standard for patent protection that was
to be reflected in the domestic laws of all WTO members. In terms of medicinal patents,
the TRIPS Agreement allows inventors to hold the sole rights to the product or process
for a minimum of twenty years—a coup for the U.S. pharmaceutical industry.
Economists estimated that the implementation of the “TRIPS agreement was… expected
to bring between $2.1 and $14.4 billion in additional profits to pharmaceutical companies
in developed countries.” 13 While the benefits of the agreement for these corporations are
clear, the repercussions on the developing world are starkly different.
Basic economic principles dictate that creating a monopoly for a product allows
the corporation to charge a higher price seeing as there are no cheaper alternatives
9
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available. The “rule-of-fives” theory for drug prices “indicates that the lowest prices
generally are achieved only when there are five therapeutic alternatives or five competing
producers.” 14 The difference in price between the original, patented drug and the generic
versions is enormous. For a hundred units of Ciprofloxacin, a drug that treats multiresistant tuberculosis, Bayer will charge somewhere between $169 and $549. The generic
version from India is sold for $10. 15 Even when drug companies reduce their prices in
impoverished countries, the generic versions are still significantly cheaper. A
combination of AZT and 3TC, both used to treat HIV/AIDS, is sold for $18 a day in the
United States. GlaxoSmithKline reduces that price to $7 a day in Uganda. Still, the same
drug, produced in Brazil, is marketed for a mere $1.50. 16 This price disparity translates to
the difference between life and death for millions of people.
While an undoubtedly complicated issue, the reality is that many of these essential
drugs are simply too expensive for the majority of the developing world. Per capita health
expenditures amount to barely $3 in Burundi and only $5 in Nepal. 17 A total of 61
countries have public drug expenditures of less than $10 per capita. 18 Compare that to the
several thousand dollars that one-year’s worth of tri-therapy HIV medicine can cost.
Households, burdened by a poverty that is only intensified by disease, are even less likely
to be able to pay for more expensive drugs. Because of the low government expenditures
on health care in developing countries, poor citizens are already forced to take on a much
larger proportion of these costs personally. For example, 85% of healthcare costs in India

14

“More Equitable Pricing for Essential Drugs: What Do We Mean and What Are the Issues?” The World
Health Organization. Geneva: WHO, 2001. 16 Oct. 2006, 17.
15
Bailey, 17.
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Ibid.
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come out of the patients’ own pockets. 19 Oxfam International conducted a survey that
showed three-quarters of poor urban households in Kampala, Uganda cut spending on
food to pay for medicine. 20 This problem is enormous, and though not solving it entirely,
generic manufacturers do provide essential medicines to demographics that are widely
excluded by the high prices of Western drug makers.
At the 2001 Doha ministerial meeting, after great controversy over the original
TRIPS Agreement and its effect on developing nations, WTO members signed the
Declaration on the TRIPS Agreement and Public Health. It stated that the TRIPS
Agreement “should not prevent Members from taking measures to protect public
health…[and] to promote access to medicines for all.” 21 The TRIPS Agreement allows
governments to refuse “to issue a patent for an invention if its commercial exploitation is
prohibited for reasons of public order or morality.” 22 These added flexibilities are a
significant step toward allowing countries to address urgent national emergencies.
However, the pharmaceutical industry continues to heavily lobby the U.S. government,
which, in turn, simply seeks the more stringent patent protection in its bilateral trade
agreements while threatening sanctions on developing countries who refuse to enforce
these intellectual property laws. The issue of access to essential medicines in poor nations
is incredibly complex and the product of many factors—extreme poverty, corruption, and
poor infrastructure to name a few. However, high prices spawned from monopolistic
patent policies are one important facet of the issue. As long as pharmaceutical

19
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Bailey, 14.
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corporations continue to endorse and fight for these policies, they will effectively negate
much of the good work they currently do in the developing world.
Slanted Research and Development
When trying to assess the priorities of Western pharmaceutical companies, it is
wise to first survey the medicines they have developed over the years. A cursory look
will show a notable dearth in research for the diseases that primarily target poor
populations. Only “ten percent of health research targets the illnesses that make up 90
percent of the global disease burden. A miserly 0.2 percent of research efforts are
directed to diarrhea, pneumonia and TB, which cause 18 percent of all illness.” 23 Less
than 0.5 of global drug development is directed to malaria research.24 Only eight of the
1,233 drugs licensed by the U.S. Food and Drug Administration from 1975 to 1997 were
developed specifically for tropical diseases in humans. 25 PhRMA argues that global
patent protection is necessary to promote future R&D, but it is overtly clear that this
future R&D is unlikely to reflect the diseases that plague the populations that most need
cheaper, generic drugs in the first place.
It is entirely logical for pharmaceutical companies to devote a relatively small
percent of their resources to developing treatments for “poor people diseases.” Were
they to discover an effective new drug, there would still be no market for the medicine
despite the millions it could save. The populations that most need these drugs simply
cannot afford to pay the prices that would produce a viable incentive to incur steep
R&D costs. Even for diseases that affect the wealthy and impoverished alike, it is not

23

Bailey, 5.
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the poor that are enticing pharmaceutical corporations to develop new treatments. For
instance, countries with a cumulative fifty-percent of the world’s population “contribute
less than two percent to spending on cardiovascular drugs.” 26 As our world becomes
increasingly smaller and integrated through globalization, large multinational
corporations such as Merck and Roche are forced to reevaluate the way they do
business and direct their resources. Their products are introduced into previously
untapped markets, but is that really enough to alter the allocation of funds for research
and development? As of now, it appears as though pure market forces are overriding
humanitarian impulses.
Refocusing Responsibility
When allocating blame for issues as complex as a global health crisis, billion
dollar corporations make for easy targets. Recent Hollywood productions, like The
Constant Gardner, depict the pharmaceutical industry as willing to sacrifice anything in
order to reap a profit. But is focusing so much critical attention on the practices of
pharmaceutical companies really productive? Certainly their role in developing lifesaving drugs places them in a separate category that deserves careful scrutiny, but are our
expectations of these companies unrealistic or even unfair? Pharmaceutical corporations
survive off commercial success and, like any business, they will logically promote
policies that can help foster this success. In this case, that may equate to supporting strict
patent protection in developing countries or aligning R&D to target more profitable drugs
like Prozac or Viagra. When looked at through this paradigm, the question is not why
pharmaceutical companies do not support more humanitarian work. Instead, we must ask
ourselves, what motivates them to do any at all? The cynic might argue that it provides
26

Lanjouw
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an agreeable public image for marketing purposes. While this is certainly true, I would
argue that it also signals the industry’s acknowledgment of its critical role in battling the
global health crisis and its inherent humanitarian obligations.
I, by no means, hope to excuse pharmaceutical corporations, or any corporations
for that matter, from social and ethical accountability. As an undeniable force that
permeates health, politics and development, they should be openly chastised when they
endorse harmful policies or partake in ethically hazy practices. I only fear that placing so
much attention and responsibility on this industry will result in little progress besides
assigning an effective scapegoat. If we accept that pharmaceutical companies will act
first and foremost in the interest of their businesses, then we can move on to develop new
strategies to curb the possible ramifications this will have on treating the world’s poor.
For example, if the pharmaceutical lobby will fight for patents on essential medicines in
developing countries, how can we keep this influence from denying affordable medicine
to the millions dying of treatable disease? The WTO’s changes to the TRIPS Agreement
to better account for public health concerns prove that nations can, in fact, come together
to seek a fairer solution. Yes, the pharmaceutical industry is powerful, but it is ultimately
the United States government that is responsible for enacting policies that demand this
strict patent protection. When addressing the issue of affordable drugs, we must look to
the state and our nation’s leaders to act justly and promote health throughout the globe,
even if it means denying the pharmaceutical lobby.
While pharmaceutical companies will most likely continue to focus their R&D on
profitable treatments, we must be creative in addressing the severe lack of research into
diseases plaguing the poor. Wealthy governments should provide greater funds to
specifically research infectious diseases and deadly epidemics such as HIV/AIDS and
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tuberculosis. Perhaps a separate fund should be established to focus on these particular
illnesses or such an entity could also be linked to an agency such as the World Health
Organization. New actors following different models also show great promise in tackling
these issues. One World Health, the first non-profit pharmaceutical company in the
United States, seeks out drugs that have been “developed by industry that could be
targeted at devastating illnesses in impoverished countries.” 27 The pharmaceutical
industry, in its early stages of research, finds a number of positive leads that could
develop into potential drugs. However, these drugs are often shelved due to lack of
commercial prospects. One World Health identifies these drug leads, secures the
intellectual property, and then fully develops the drug, seeing it through the clinical trials
and regulatory approval phases. Afterwards, it partners with a manufacturing company to
cheaply produce the drug and later with national health ministries and NGOs to secure its
distribution. 28 Certainly, One World Health’s non-profit model has its own limitations
and is unlikely to become the norm for pharmaceutical companies. However, it is a
perfect example of why we must understand how the pharmaceutical industry operates so
that other actors with different incentives can better harness its work for humanitarian
purposes.
The dire reality of the global health situation has dragged pharmaceutical
corporations into the humanitarian realm and forced us to reevaluate our view of the
industry. In a globalized society where the troubles of one region can so easily affect the
populations of another, the health crises of the developing world are truly disastrous for
27

Corcoran, Elizabeth. “The Irony of Large Numbers.” Forbes. 9 Oct. 2006.
<http://www.forbes.com/technology/2006/10/08/benetech-philanthropy-fruchterman-techcz_ec_1009valleyletter.html>
28
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all. As the pioneers in medical innovation, pharmaceutical companies are not only faced
with corporate responsibility but should also see themselves in terms of social
responsibility. Unfortunately, however, we are confronted with the certainty that they will
often fall short of the ethical standard with which we measure them. We must
acknowledge the truth that these companies will and must operate first as businesses.
While we should certainly encourage practices such as lowering prices in poor regions
and sponsoring drug donation programs, but we must look to governments, multilateral
institutions and other innovative non-governmental actors to pick up where the industry
fails.
The actions of many pharmaceutical companies are seemingly paradoxical—
working to save lives in the developing world while perpetuating policies that harm these
very countries. The contradiction becomes much more understandable after readjusting
one’s expectations of these corporations as humanitarian actors. To assume that they
should act purely benevolently is both naïve as well as counterproductive. To make any
progress in battling the countless health crises that plague the world today, we must first
acknowledge the actors involved, understand the roles they can reasonably play, and then
focus on how they must interact with each other to best address some of the gravest
threats facing society. This alone is not the grand solution that so many seek, but it is an
essential beginning to one. A better, more realistic understanding of the pharmaceutical
industry may, in fact, prove to be the most essential medicine of all.
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